]>
IRCT20211126053183N1 IRCT 2021-12-13 Shiraz University of Medical Sciences The effect of curcumin supplementaion on clinical symptoms , acute phase reactants and inflamatory cytokines in patients with covid-19 hospitalization The effect of curcumin supplementaion on clinical symptoms , acute phase reactants and inflamatory cytokines in patients with covid-19 hospitalization 2021-12-11 anticipated 76 Complete https://irct.ir/trial/60403 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We will classify patients in group A or B using a simple randomization method using the random number table tool. Which group belongs to group A or group B is also done randomly. Randomization is done by a statistical consultant who is in the stage of implementing the research project without responsibility. The main researcher and the doctor and the patient have no role in the randomization process and completely without Are informed, Blinding description: The prescribing physician and patients participating in the research project are unaware that they have received the drug or placebo. 3 covid-19. Intervention 1: Intervention group: They receive 4 capsules of curcumin 40 mg daily made by Elixir Nano Drug Company for 14 days. Intervention 2: Control group: receive 4 placebo daily for 14 days. Yes - There is a plan to make this available What will be shared: A report on which patients are in the medication or placebo group, as well as a report on test results and questionnaires will be available When: 9 months after publication Results To whom: Our data will be accessible to those who are academic and scientific researchers Conditions: The use of data for the development of other clinical trial studies or meta-analysis studies is unrestricted Where to obtain: Send email to ahmadi.sedigheh@ymail.com or sjm@sums.ac.ir How to obtain: 9 months after the publication of the article, an email will be sent to the listed address and the results will be sent within 2 month Comments:
public seyed jalil masoumi
roshd center ,neshat Ave,shiraz
shiraz Iran (Islamic Republic of) 7134874853 +98 71 3233 2313 sjm@sums.ac.ir Shiraz University of Medical Sciences scientific sedigheh ahmadi
25/4,farhang shahr Ave,shiraz
shiraz Iran (Islamic Republic of) 71859-39688 +98 71 3634 5074 ahmadi.sdigheh@ymail.com Shiraz University of Medical Sciences Iran (Islamic Republic of) They have a positive PCR test or lung involvement in the imaging and 2- Hospitalized patients who are non-intubated. 3- They are over 18 years old .4- They have filled in the informed consent form5. 5-They are not pregnant or breastfeeding.6-They do not have gallbladder inflammation or active gastrointestinal ulcers.7. They do not have hemophilia or coagulation disease.8- renal failure with GFR <30 ml / min or dialysis patients.9- Signing informed written consent.10. Not participating in other clinical trials at the same time 11.cancer patients 18 years no limit Both 1-Patients who are allergic to turmeric or curcumin.2- renal disease "GFR <30 ml / min" or dialysis patie.3-Patients who do not take more than a quarter of curcumin supplements during the study period.4- Connecting the patient to the ventilator Treatment - Other Placebo Intervention group: They receive 4 capsules of curcumin 40 mg daily made by Elixir Nano Drug Company for 14 days. Control group: receive 4 placebo daily for 14 days Albumin, ferritin,CRP, ESR, interleukin 6,WBC,total lymphocyte count(TLC) Alanine Aminotransferase(ALT)(ALT),Aspartate Amino transferase(AST),LDH, resperatory oxygen saturation (SpO2) Nutritional Risk Index (NRI). Timepoint: The first day of study, the fourteenth day of study. Method of measurement: Blood test, Nutritional Risk Index questionnaire. Shiraz University of Medical Sciences Approved 2021-10-17 Ethics committee of Shiraz University of Medical Sciences amir 3,25/4 farhang shahr ,shahid rajaee Blvd ,shiraz shiraz Fars Iran (Islamic Republic of)